1. Home
  2. News
  3. Amplia Therapeutics Ltd.
  4. Dose Escalation Approved in ACCENT Clinical Trial of AMP945
More Amplia Therapeutics Ltd. news
Amplia Therapeutics Ltd.ASX: ATX

Dose Escalation Approved in ACCENT Clinical Trial of AMP945

Apr 11, 2023 at 2:38 AM EDT · Issued by Amplia Therapeutics Ltd.

Filed with ASX · Apr 11, 2023 at 2:38 AM EDT · 2 pages · English

On 6ix: 6ix.com/news/dose-escalation-approved-in-accent-clinical-trial-of-amp945

Amplia Therapeutics Ltd. on 6ix

Earlier from Amplia Therapeutics

  • First Patient Recruited to Cohort 2 of Accent TrialFeb 1, 2023
  • Quarterly Activities and Cashflow Reports - December 2022Jan 29, 2023
  • Letter to Shareholders End of Year Summary and 2023 PlansDec 19, 2022
  • Appendix 4D and Financial Report Half Year ended 30 Sep 22Nov 17, 2022
  • Amplia Appoints Dr Christopher Burns CEO & Managing DirectorNov 6, 2022

Later from Amplia Therapeutics

  • First Patient Recruited to Cohort 3 of ACCENT TrialApr 18, 2023
  • Quarterly Activities and Cashflow Reports - March 23 QtrApr 26, 2023
  • ACCENT Trial Recruitment ProgressMay 9, 2023
  • Amplia receives grant to collaborate with CSIROMay 21, 2023
  • Grant to collaborate with CSIRO Supplementary AnnouncementMay 23, 2023
All Amplia Therapeutics news releases↗

Follow Amplia Therapeutics into a list and get an email when it puts out news.

Follow Amplia Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer